Donatienne T.
- Country
- Belgium
- Department
- Oncology
Research Overview
- Phase III Randomized Double‑Blind Placebo‑Controlled Trial of Low‑Dose Acetylsalicylic Acid for Recurrence and Overall Survival in Resected Stage II–III Colon Cancer
- Comparison of RO7771950 plus combination therapy versus tucatinib plus combination therapy in pretreated HER2-positive locally advanced or metastatic breast cancer
- A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER
Data & Insights
Has run more than one trial at 404 of 747 partner sites.
Specializations
Breast Cancer Research
Specialized in investigating diverse therapeutic approaches for breast cancer, with particular focus on hormone receptor-positive and HER2-negative variants. Conducts research on novel treatments including targeted therapies and immunotherapies.
- Early-stage breast cancer interventions
- Triple-negative breast cancer treatments
- Advanced metastatic breast cancer therapies
Gastrointestinal Oncology
Focuses on therapeutic innovations in colorectal cancer and rectal cancer treatment, particularly investigating combination therapies and novel treatment approaches for metastatic disease.
- Metastatic colorectal cancer treatments
- Locally advanced rectal cancer management
- Adjuvant therapy strategies
Head and Neck Cancer
Investigates innovative treatments for head and neck squamous cell carcinoma, with emphasis on immunotherapy combinations and targeted approaches for recurrent or metastatic disease.
- First-line treatment strategies
- PD-L1 positive cancer therapies
- Combination immunotherapy approaches
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.